Sepsis remains the leading cause of death in critical care units of hospitals, affecting more that 18 million people worldwide, and causes a systemic inflammatory response driven by the production of proinflammatory cytokines. Although the currently available biomarkers can help shorten patients at risk, there is still a need for robust early disease biomarkers that could anticipate the decision-making identifying immunocompromised septic patients. Our group have determined that during the initial 24 h of sepsis, blood monocytes from human septic patients present an early impairment of the activation of the NLRP3 inflammasome that is associated with higher late complications and mortality. This group of septic patients was not identified with any of the clinical or biochemical determinations performed in the clinical routine or by measuring novel experimental biomarkers published by other groups. Using our generated knowledge, we have developed and patented an in vitro prognostic (IVD) method for the fast detection, in less than 4 hours, of early impairment of the NLRP3 inflammasome activation by blood cell culture (TRL4). Our initial market and business analysis for the viability and use of such IVD in sepsis has reveal that point-of-care devices for sepsis able to early stratify patients are urgently needed, being large companies active in the sepsis market willing to acquire new technologies. The objectives of this project is to develop a prototype of point-of-care device using our patented technology and evaluate product engineering aspects to define the regulatory roadmap.
Sepsis
método pronóstico
equipo de punto de atención
inflamasoma NLRP3
estratificación de pacientes
Acción Estratégica en Salud (AES)
01/01/2022 - 31/12/2023
PABLO, PELEGRIN VIVANCOS
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)
MURCIA
MURCIA
88,000 €